Information Provided By:
Fly News Breaks for August 3, 2017
KIN
Aug 3, 2017 | 08:39 EDT
Aegis analyst Benjamin Haynor said his survey of 321 veterinarians gave him confidence that his Mirataz pricing model of $1.50/day is reasonable and that his 2018 estimates for the drug are likely to be "highly conservative." Haynor, who believes Kindred Biosciences should see rapid uptake of Mirataz, keeps a Buy rating and $11.50 price target on the stock.
News For KIN From the Last 2 Days
There are no results for your query KIN